SRR23303738
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.310
- KRAS_SIGNALING_DN+0.260
- E2F_TARGETS+0.230
- PANCREAS_BETA_CELLS+0.230
- ALLOGRAFT_REJECTION+0.210
- G2M_CHECKPOINT+0.180
- OXIDATIVE_PHOSPHORYLATION+0.130
- ESTROGEN_RESPONSE_LATE+0.110
- BILE_ACID_METABOLISM+0.090
- FATTY_ACID_METABOLISM+0.060
Top 10 suppressed
- TGF_BETA_SIGNALING-0.630
- WNT_BETA_CATENIN_SIGNALING-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.510
- PROTEIN_SECRETION-0.480
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- HEDGEHOG_SIGNALING-0.430
- PI3K_AKT_MTOR_SIGNALING-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- CHOLESTEROL_HOMEOSTASIS-0.400
- HYPOXIA-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG159 | — | — | 0.813 |
| 2 | MDT-AP-1141 | Med | Medulloblastoma | 0.812 |
| 3 | MDT-AP-1162 | Med | Medulloblastoma | 0.808 |
| 4 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.806 |
| 5 | SRR8392892 | — | cohortA1 | 0.799 |
| 6 | MNG913 | — | — | 0.798 |
| 7 | SRR25617831 | — | D | 0.796 |
| 8 | R283 | — | — | 0.793 |
| 9 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.787 |
| 10 | R227 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.020 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |